Work

Omecamtiv mecarbil for heart failure: Unpacking the latest systematic review and meta-analysis

Year: 2024

Type: review

Abstract: In February 2023, a systematic review and meta-analysis of six randomized controlled trials (RCTs) with a total of 9,596 patients assessed the effectiveness and safety of omecamtiv mecarbil (OM) versus placebo in patients with heart failure with reduced left ventricular ejection fraction (HFrEF). HFrEF is a significant health problem associated with high morbidity and mortality worldwide. OM is a novel drug that targets cardiac myosin, a cytoskeletal motor protein responsible for converting chemical energy to mechanical force.

Source: International Journal of Cardiology and Cardiovascular Diseases

DOI: 10.46439/cardiology.4.028

Author: Ramzi Ibrahim

Institution: University of Arizona

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4407808401